All In Biotech

Investigational drug · Phase 3

cannabidiol as a clear that can be applied to the skin

Also called: ZYN002, transdermal delivery

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Fragile X Syndrome, Fragile X Syndrome (FXS).

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

1

Any phase or sponsor naming "cannabidiol as a clear that can be applied to the skin"

First trial start

2021

Sep 13, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "cannabidiol as a clear that can be applied to the skin", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Fragile X Syndrome
  • Fragile X Syndrome (FXS)

Approved drugs for the same conditions: Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "cannabidiol as a clear that can be applied to the skin" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 4,978 on PubMed

Also in development for Fragile X Syndrome

  • BPN14770zatolmilastPhase 34 trials

    Tetra Discovery Partners · Fragile X Syndrome, Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder

  • SPG601CodabakalnerPhase 32 trials

    Spinogenix · Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD), Fragile X Syndrome

  • CTH120Phase 21 trial

    Connecta Therapeutics, S.L. · Fragile X Syndrome (FXS), Fragile X Syndrome

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.